Lung Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Lung Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month45 studies across 26 companies, in the next 180 days.
August 2026 6
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals | A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryNCT06161441Pathological complete response (pCR) as evaluated by blinded independent pathological review (BIPR) in post-treatment resected tumor samples | Phase 2 | Active, not recruiting | 2026-08-24 | in 4 d | 2026-08-10 |
| AZN | AstraZeneca | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCNCT04995523Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters | Phase 1/2 | Active, not recruiting | 2026-08-28 | in 8 d | 2026-07-14 |
| PFE | Pfizer | A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLCNCT07556549observationalAge at Start of Lorlatinib Treatment | — | Active, not recruiting | 2026-08-30 | in 10 d | 2026-08-10 |
| AZN | AstraZeneca | A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in BrazilNCT06008353observationalDemographic Characteristics of the Cohort | — | Active, not recruiting | 2026-08-31 | in 11 d | 2024-12-19 |
| NRIX | Nurix Therapeutics, Inc. | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | 2026-08-31 | in 11 d | 2025-09-09 |
| RADX | Radiopharm Theranostics, Ltd | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsNCT05799274Radiation dosimetry of RAD301 | Phase 1 | Recruiting | Aug 2026 | ≤ 11 d | 2026-07-17 |
September 2026 5
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerNCT05221840Progression Free Surival (PFS) | Phase 3 | Active, not recruiting | 2026-09-30 | in 41 d | 2026-06-18 |
| AZN | AstraZeneca | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06417814Progression free Survival (PFS) | Phase 3 | Recruiting | 2026-09-30 | in 41 d | 2026-05-14 |
| BMY | Bristol-Myers Squibb | Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and CanadaNCT07718139observationalNumber of participants with pathological complete response after neoadjuvant immunotherapy and surgical resection. | — | Active, not recruiting | 2026-09-30 | in 41 d | 2026-07-21 |
| GILD | Gilead Sciences | Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)NCT05186974Objective Response Rate as Assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Phase 2 | Active, not recruiting | Sep 2026 | ≤ 41 d | 2026-02-11 |
| TNGX | Tango Therapeutics, Inc. | Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsNCT05887492Determine the MTD and RP2D(s) (Phase 1 only) | Phase 1/2 | Active, not recruiting | Sep 2026 | ≤ 41 d | 2026-07-06 |
October 2026 5
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.NCT06447662Part 1 & 2: Incidence of Adverse Events (AEs) | Phase 1 | Active, not recruiting | 2026-10-09 | in 50 d | 2026-07-22 |
| TEM | Tempus AI | Tempus Priority Study: A Pan-tumor Observational StudyNCT05179824observationalCreate robust data set of health information | — | Active, not recruiting | 2026-10-19 | in 60 d | 2025-05-06 |
| AZN | AstraZeneca | A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASNCT06008093Progression-free survival (PFS) in randomized participants | Phase 2 | Active, not recruiting | 2026-10-23 | in 64 d | 2026-07-02 |
| AMGN | Amgen | Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).NCT06333951Number of Participants Experiencing Dose Limiting Toxicities (DLT) | Phase 1 | Active, not recruiting | 2026-10-31 | in 72 d | 2026-05-28 |
| IDYA | IDEAYA Biosciences | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDE | Phase 1 | Active, not recruiting | Oct 2026 | ≤ 72 d | 2026-07-13 |
November 2026 4
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | Safety and Efficacy of Xalkori ROS1NCT03375242observationalThe incidence of adverse drug reactions in this surveillance. | — | Active, not recruiting | 2026-11-06 | in 78 d | 2026-03-30 |
| EXEL | Exelixis | Study of XB010 in Subjects With Solid TumorsNCT06545331Dose-Escalation Stage: Maximum tolerated dose (MTD) and/or Recommended dose(s) for Expansion [RDE(s)] for XB010 | Phase 1 | Recruiting | 2026-11-23 | in 95 d | 2026-06-22 |
| AZN | AstraZeneca | Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.NCT06376097observationalAbsolute number and frequency of false-negative lung nodules . | — | Recruiting | 2026-11-29 | in 101 d | 2026-08-03 |
| MGNX | MacroGenics | A Study of MGC028 in Participants With Advanced Solid TumorsNCT06723236Number and Types of Adverse Events (AEs) in Participants Receiving MGC028 | Phase 1 | Recruiting | Nov 2026 | ≤ 102 d | 2026-04-27 |
December 2026 18
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | Lorlatinib Continuation StudyNCT05144997Number of participants with adverse events leading to permanent discontinuation of study intervention | Phase 4 | Active, not recruiting | 2026-12-28 | in 130 d | 2025-12-17 |
| 000100.KS | Yuhan Corporation | Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR MutationNCT06247280observationalClinical characteristics of NSCLC patients with EGFR mutation | — | Active, not recruiting | 2026-12-31 | in 133 d | 2024-12-06 |
| AMGN | Amgen | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)NCT03319940Number of participants with dose limiting toxicities (DLT) for all indications | Phase 1 | Active, not recruiting | 2026-12-31 | in 133 d | 2025-11-19 |
| AZN | AstraZeneca | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursNCT06147037Evaluate safety and tolerability of [111In]-FPI-2107, FPI-2053, and [225Ac]-FPI-2068 | Phase 1 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-07-07 |
| AZN | AstraZeneca | RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in BrazilNCT06491862observationalDescribe the patient population and treatment patterns | — | Recruiting | 2026-12-31 | in 133 d | 2026-07-22 |
| BMY | Bristol-Myers Squibb | A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in JapanNCT05161325observationalDuration of treatment | — | Active, not recruiting | 2026-12-31 | in 133 d | 2026-06-02 |
| CMPX | Compass Therapeutics | A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesNCT06150664Cohort 1: Evaluate the safety and tolerability of escalating doses of CTX-8371 | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2026-07-28 |
| EIKN | Eikon Therapeutics | A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCNCT06246110Percentage of participants with safety event during treatment | Phase 2 | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-05-28 |
| GH | Guardant Health, Inc. | Screening for High Frequency Malignant DiseaseNCT05117840observationalPerformance characteristics of Guardant LUNAR-2 test | — | Active, not recruiting | 2026-12-31 | in 133 d | 2026-07-06 |
| JAZZ | Jazz Pharmaceuticals | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | 2026-12-31 | in 133 d | 2026-07-10 |
| LTRN | Lantern Pharma Inc. | A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaNCT05456256Progression-free survival (PFS) | Phase 2 | Recruiting | Dec 2026 | ≤ 133 d | 2026-05-04 |
| MNPR | Monopar Therapeutics | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsNCT06617169Identify the dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequency | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2025-05-21 |
| NVCT | Nuvectis Pharma, Inc. | Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung CancerNCT07315113Number of patients with treatment related adverse events and/or clinical laboratory abnormalities | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2026-07-09 |
| NXTC | NextCure, Inc. | A Phase 1 Study of LNCB74 in Advanced Solid TumorsNCT06774963Evaluate the safety and tolerability of LNCB74 | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2025-12-16 |
| ORIC | ORIC Pharmaceuticals | ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLCNCT06816992Recommended Phase 2 Dose (RP2D) | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2026-04-24 |
| PFE | Pfizer | PF-07104091 as a Single Agent and in Combination TherapyNCT04553133Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle | Phase 2 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-05-06 |
| PFE | Pfizer | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingNCT05059522Number of participants with adverse events leading to permanent discontinuation of study intervention | Phase 3 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-06-22 |
| RVMD | Revolution Medicines, Inc. | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsNCT06040541Adverse events | Phase 1 | Recruiting | 2026-12-31 | in 133 d | 2026-06-03 |
January 2027 5
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| 4568.T | Daiichi Sankyo Co., Ltd. | First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)NCT03401385Number of participants with dose-limiting toxicities | Phase 1 | Active, not recruiting | 2027-01-01 | in 134 d | 2025-10-21 |
| AZN | AstraZeneca | Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCNCT05374603PFS | Phase 2 | Active, not recruiting | 2027-01-18 | in 151 d | 2026-05-14 |
| AZN | AstraZeneca | Lung Cancer Screening Implementation Project in the Brazilian Public Health Care System (LUSIP)NCT07279948observational• Proportion of negative cases on screening according to the Lung-RADS classification. | — | Not yet recruiting | 2027-01-31 | in 164 d | 2026-08-03 |
| EXEL | Exelixis | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | 2027-01-31 | in 164 d | 2026-08-05 |
| KURA | Kura Oncology, Inc. | KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsNCT06026410Rate of dose-limiting toxicities (DLTs) | Phase 1 | Recruiting | Jan 2027 | ≤ 164 d | 2026-06-08 |
February 2027 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)NCT06946797Maximum observed serum concentration (Cmax) of subcutaneous Nivolumab in serum | Phase 2 | Active, not recruiting | 2027-02-05 | in 169 d | 2026-05-14 |
| 4568.T | Daiichi Sankyo | Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)NCT06809764observationalProgression-free survival (PFS) by Investigator Assessment in Real-world Setting (rwPFS) | — | Recruiting | 2027-02-12 | in 176 d | 2026-08-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Lung Cancer
most recently updated first1,161 studies match. Showing the first 100 of 1,161 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesNCT04644068The number of subjects with adverse events/serious adverse events | Phase 1/2 | Active, not recruiting | Drug: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant | Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5 | 702 | 2020-11-12 | 2027-05-28 | in 281 d | 2026-08-19 |
| 4568.T | Daiichi Sankyo | $31.7B | Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsNCT05215340Progression-free Survival Based on Blinded Independent Central Review in Participants With Non-Squamous Histology Who Were Administered Dato-DXd in Combination With Pembrolizumab Compared With Pembrolizumab | Phase 3 | Active, not recruiting | Drug: Datopotamab Deruxtecan, Pembrolizumab | Metastatic Non Small Cell Lung Cancer | 740 | 2022-03-04 | 2030-03-04 | in 1,292 d | 2026-08-19 |
| BOLD | Boundless Bio, Inc. | $65M | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsNCT05827614Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-355 as a single agent and in combination with each of the following agents: erlotinib, futibatinib, or BBI-825 | Phase 1 | Terminatedsponsor's stated reason: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal. | Drug: BBI-355, Erlotinib, Futibatinib, BBI-825 | Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer | 85 | 2023-03-24 | 2026-03-17actual | — | 2026-08-19 |
| ONC | BeOne Medicines | $545.6B | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: BGB-43395, Fulvestrant, Letrozole, Elacestrant, Anti-Diarrheal Agent | Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer | 399 | 2023-12-01 | Nov 2028 | ≤ 833 d | 2026-08-19 |
| AZN | AstraZeneca | — | To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR MutationsNCT06194448PFS (Progression-Free Survival) | Phase 2 | Active, not recruiting | Drug: Osimertinib, Cisplatin or Carboplatin; Pemetrexed or Paclitaxel, Radiation | Lung Cancer | 76 | 2024-04-21 | 2026-07-07actual | — | 2026-08-19 |
| SMMT | Summit Therapeutics | $10.2B | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1NCT06767514Overall Survival (OS) | Phase 3 | Recruiting | Biological: Ivonescimab Injection, Pembrolizumab Injection | Non-Small Cell Lung Cancer | 780 | 2025-02-27 | Apr 2028 | ≤ 619 d | 2026-08-19 |
| AZN | AstraZeneca | — | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsNCT07115043Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion) | Phase 1/2 | Recruiting | Drug: AZD6750, rilvegostomig | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma | 120 | 2025-07-29 | 2029-10-02 | in 1,139 d | 2026-08-19 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerNCT07365241Objective Response (OR) as Measured by Overall Response Rate (ORR) Based on Blinded Independent Central Review (BICR) | Phase 3 | Recruiting | Drug: ABBV-706, Topotecan, Topotecan, Lurbinectedin, Amrubicin | Small Cell Lung Cancer | 531 | 2026-07-02 | Sep 2030 | ≤ 1,502 d | 2026-08-19 |
| AZN | AstraZeneca | — | A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLCNCT05246514results2024-12-04ICR-assessed ORR (Objective Response Rate) | Phase 2 | Active, not recruiting | Drug: Trastuzumab deruxtecan | HER2-mutant Non-Small Cell Lung Cancer | 72 | 2022-07-13 | 2024-11-04actual | — | 2026-08-18 |
| AZN | AstraZeneca | — | Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLCNCT06376084observationalReal-World Progression Free Survival (rwPFS) | — | Active, not recruiting | — | Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms | 532 | 2024-07-23 | 2028-02-28 | in 557 d | 2026-08-18 |
| AZN | AstraZeneca | — | A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological FeaturesNCT06564844Disease-Free Survival (DFS) using BICR in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC | Phase 3 | Active, not recruiting | Drug: Datopotamab Deruxtecan, Rilvegostomig, Carboplatin, Cisplatin, Etoposide, Pemetrexed, Vinorelbine, UFT | Non-small Cell Lung Cancer | 25 | 2024-10-15 | 2027-06-30 | in 314 d | 2026-08-18 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsNCT06618287Number of participants with adverse events (AEs) | Phase 1/2 | Recruiting | Drug: BMS-986507, Osimertinib, Pembrolizumab, Nivolumab, Pumitamig | Lung Cancer, Breast Cancer | 416 | 2025-02-04 | 2031-02-26 | in 1,651 d | 2026-08-18 |
| 4568.T | Daiichi Sankyo | $31.7B | Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)NCT06809764observationalProgression-free survival (PFS) by Investigator Assessment in Real-world Setting (rwPFS) | — | Recruiting | Other: No drug | Non-small Cell Lung Cancer | 150 | 2025-02-21 | 2027-02-12 | in 176 d | 2026-08-18 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung CancerNCT07325136Number of participants with adverse events (AEs) | Phase 1/2 | Recruiting | Drug: BMS-986525, Pumitamig | Relapsed/Refractory Small Cell Lung Cancer | 240 | 2026-02-03 | 2029-04-23 | in 977 d | 2026-08-18 |
| INCY | Incyte Corporation | $24.7B | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibNCT02955940Frequency and types of adverse events and serious adverse events | Phase 2 | Active, not recruiting | Drug: Ruxolitinib, Capecitabine, Regorafenib | Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer | 10 | 2016-11-30 | 2027-09-30 | in 406 d | 2026-08-17 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsNCT04895709Incidence of adverse events (AEs) | Phase 1/2 | Recruiting | Drug: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig | Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms | 1,109 | 2021-05-27 | 2031-08-31 | in 1,837 d | 2026-08-17 |
| PBYI | Puma Biotechnology, Inc. | $477M | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerNCT06095505Objective response rate (ORR) within biomarker-defined subgroup | Phase 2 | Recruiting | Drug: Alisertib | Small Cell Lung Cancer | 120 | 2024-02-08 | 2027-10-30 | in 436 d | 2026-08-17 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%NCT06561386Overall survival (OS) in randomized participants with PD-L1 1% to 49% | Phase 3 | Recruiting | Drug: Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin | Non-small Cell Lung Cancer | 1,000 | 2024-10-07 | 2030-07-30 | in 1,440 d | 2026-08-17 |
| 000100.KS | Yuhan Corporation | $4.2B | A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946NCT06616766Treatment Emergent Adverse Events(TEAE)s | Phase 1/2 | Recruiting | Drug: YH42946 | NSCLC (Non-small Cell Lung Cancer), Solid Tumor | 201 | 2024-10-02 | 2028-03-15 | in 573 d | 2026-08-17 |
| AMGN | Amgen | $229.9B | A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLCNCT06745323Proportion of participants with confirmed objective response to Tarlatamab | Phase 2 | Active, not recruiting | Drug: Tarlatamab | Small Cell Lung Cancer (SCLC) | 252 | 2025-02-26 | 2029-05-10 | in 994 d | 2026-08-17 |
| NXTC | NextCure, Inc. | $30M | A Phase I Study of SIM0505 in Participants With Advanced Solid TumorsNCT06792552dose escalation: Dose-limiting toxicity (DLT) | Phase 1 | Recruiting | Drug: SIM0505 for injection, SIM0505 for injection | Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC), Papillary Renal Cell Carcinoma (Prcc), Uterine Serous Carcinoma (USC), NSCLC (Non-small Cell Lung Cancer), Primary Peritoneal Cancer | 738 | 2025-02-26 | Feb 2028 | ≤ 558 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280Overall Survival | Phase 3 | Recruiting | Drug: PF-08046054, Docetaxel monotherapy | Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma | 680 | 2025-09-29 | 2028-03-10 | in 568 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT07222566Overall Survival | Phase 3 | Recruiting | Biological: PF-08634404, Pembrolizumab · Drug: Chemotherapy Regimen 1, Chemotherapy Regimen 2 | Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Metastatic Non Small Cell Lung Cancer, Lung Cancer | 1,410 | 2026-01-06 | 2029-02-27 | in 922 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung CancerNCT07226999Phase 2: Confirmed Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] based on the investigator's assessment | Phase 2/3 | Recruiting | Drug: PF-08634404, Chemotherapy · Biological: Atezolizumab | Small Cell Lung Cancer (SCLC) | 550 | 2025-12-09 | 2030-06-14 | in 1,394 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung CancerNCT07476287Confirmed Objective Response Rate (ORR) as assessed by investigator based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) | Phase 2 | Recruiting | Drug: PF-08634404, Chemotherapy | Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Small Cell Lung, Small Cell Cancer Of The Lung | 40 | 2026-07-02 | 2028-03-19 | in 577 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLCNCT07489066Number of Participants With Adverse Events (AEs) | Phase 2 | Recruiting | Biological: PF-08634404 · Drug: Chemotherapy Regimen 1, Chemotherapy Regimen 2 | Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous | 120 | 2026-06-30 | 2028-07-29 | in 709 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Phase 1 Study of PF-08046033 in Advanced Solid TumorsNCT07519655Type, incidence and severity of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: PF-08046033 | Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma | 250 | 2026-04-08 | 2028-07-14 | in 694 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Tucatinib Continuation StudyNCT07768358To monitor the safety and tolerability of tucatinib | Phase 4 | Not yet recruiting | Drug: tucatinib | HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer, Advanced Non-Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer | 175 | 2026-08-24 | 2032-03-13 | in 2,032 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsNCT05538130Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with dose limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: PF-07799544, PF-07799933 | Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Advanced or Metastatic Solid Tumors, HGG, LGG, Low Grade Glioma, High Grade Glioma, Differentiated Thyroid Cancer, NSCLC (Non-small Cell Lung Cancer) | 124 | 2022-11-30 | 2027-08-02 | in 347 d | 2026-08-14 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT06568939Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2) | Phase 2 | Recruiting | Drug: Telisotuzumab Vedotin | Non-Small Cell Lung Cancer | 150 | 2025-01-20 | Feb 2028 | ≤ 558 d | 2026-08-14 |
| AZN | AstraZeneca | — | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647Overall survival (OS) | Phase 3 | Recruiting | Drug: Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed | Non-squamous Non-small Cell Lung Cancer | 1,160 | 2024-11-27 | 2030-11-18 | in 1,551 d | 2026-08-14 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).NCT06646276Overall Survival (OS) | Phase 3 | Recruiting | Biological: BMS-986489 (BMS-986012+Nivolumab), Atezolizumab · Drug: Carboplatin, Etoposide | Extensive-Stage Small Cell Lung Cancer | 530 | 2025-02-25 | 2028-04-06 | in 595 d | 2026-08-14 |
| ABBV | AbbVie | $457.5B | Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsNCT06772623Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab Adizutecan | Phase 1/2 | Recruiting | Drug: Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin | Non Small Cell Lung Carcinoma | 252 | 2025-03-06 | Nov 2027 | ≤ 467 d | 2026-08-14 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerNCT07155174Number of Participants with Adverse Events (AE)s | Phase 2 | Recruiting | Drug: ABBV-706, Atezolizumab, Etoposide, Carboplatin, Carboplatin, Lurbinectedin | Small Cell Lung Cancer | 180 | 2025-11-25 | Apr 2029 | ≤ 984 d | 2026-08-14 |
| NXTC | NextCure, Inc. | $30M | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsNCT05572684results2026-08-13Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 | Phase 1/2 | Terminatedsponsor's stated reason: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. | Drug: NC410, pembrolizumab | Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer | 97 | 2022-10-06 | 2025-04-30actual | — | 2026-08-13 |
| AMGN | Amgen | $229.9B | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)NCT05920356Progression-free Survival (PFS) | Phase 3 | Recruiting | Drug: Sotorasib, Pembrolizumab | Non-Small Cell Lung Cancer (NSCLC) | 750 | 2023-11-16 | 2027-06-30 | in 314 d | 2026-08-13 |
| RXRX | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | $1.7B | Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsNCT05985655Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 1/2 | Recruiting | Drug: GTAEXS617, SoC | Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC) | 230 | 2023-07-06 | Jan 2028 | ≤ 529 d | 2026-08-13 |
| AZN | AstraZeneca | — | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738Overall survival (OS) | Phase 3 | Recruiting | Drug: Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel | Non-small Cell Lung Cancer | 1,160 | 2024-11-18 | 2030-07-01 | in 1,411 d | 2026-08-13 |
| BNTX | BioNTech SE | — | Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung CancerNCT06712316Phase 2 - Occurrence of treatment-emergent adverse events (TEAE) (including Grade ≥3), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-emergent serious adverse events (SAE), and treatment-related treatment emergent SAEs | Phase 2/3 | Recruiting | Drug: Pumitamig, Pembrolizumab, Carboplatin, Pemetrexed, Paclitaxel | Non-small Cell Lung Cancer | 1,580 | 2025-01-07 | Jan 2029 | ≤ 895 d | 2026-08-13 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT07154290Objective response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Phase 2 | Recruiting | Drug: Ubamatamab, Marlotamig, Sarilumab | Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung | 300 | 2026-03-18 | 2030-06-10 | in 1,390 d | 2026-08-13 |
| AZN | AstraZeneca | — | Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in ChinaNCT07593248observationalTo assess the effectiveness in real world of EGFR-TKI adjuvant therapy in resected NSCLC as measured by 5-year OS rate | — | Recruiting | — | Lung Cancer | 2,000 | 2026-06-22 | 2031-06-30 | in 1,775 d | 2026-08-13 |
| AZN | AstraZeneca | — | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesNCT05123482The number of patients with adverse events | Phase 1/2 | Recruiting | Drug: AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), AZD8205 in combination with AZD9574, AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936) | Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer | 460 | 2021-10-18 | 2027-09-29 | in 405 d | 2026-08-12 |
| AZN | AstraZeneca | — | Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsNCT06357533Progression-Free Survival (PFS) in TROP2 biomarker positive participants. | Phase 3 | Recruiting | Drug: Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab | Non-Small Cell Lung Cancer | 675 | 2024-04-11 | 2029-12-28 | in 1,226 d | 2026-08-12 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerNCT06801834Overall Survival (OS) | Phase 3 | Recruiting | Drug: Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available) | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 695 | 2025-04-04 | Oct 2029 | ≤ 1,168 d | 2026-08-12 |
| RADX | Radiopharm Theranostics, Ltd | — | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.NCT07272642To assess the safety and tolerability of a single dose of LNTH-2403 | Phase 1 | Not yet recruiting | Drug: LNTH-2403 | Imaging, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC) | 16 | 2026-10-30 | 2027-08-30 | in 375 d | 2026-08-12 |
| AZN | AstraZeneca | — | A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in ChinaNCT07316062observationalTreatment Patterns | — | Recruiting | — | Non-Small-Cell Lung | 3,000 | 2026-04-29 | 2029-04-30 | in 984 d | 2026-08-12 |
| AZN | AstraZeneca | — | A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLCNCT07760519observationalFrequency and proportion of patients with Grade 3/4 possibly related adverse events (PRAEs)* | — | Not yet recruiting | Other: IMFINZI | Carcinoma, Non-Small-Cell Lung | 78 | 2026-09-30 | 2030-04-30 | in 1,349 d | 2026-08-12 |
| MGNX | MacroGenics | $261M | A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest. | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | 2024-03-06 | May 2028 | ≤ 650 d | 2026-08-11 |
| VSTM | Verastem, Inc. | $673M | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung CancerNCT07659782Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 | Phase 2 | Recruiting | Drug: VS-7375 | Non-Small Cell Lung Cancer | 105 | 2026-07-22 | Jun 2027 | ≤ 314 d | 2026-08-11 |
| ABBV | AbbVie | $457.5B | A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult ParticipantsNCT07756645Progression-Free Survival (PFS) assessed by the Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Phase 3 | Not yet recruiting | Drug: ABBV-1480, Pembrolizumab, Carboplatin, Paclitaxel, Nab- Paclitaxel | Non-Small Cell Lung Cancer | 940 | 2026-09-22 | Dec 2029 | ≤ 1,229 d | 2026-08-11 |
| PMVP | PMV Pharmaceuticals, Inc | $66M | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt | Phase 1/2 | Recruiting | Drug: rezatapopt, pembrolizumab | Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer | 300 | 2020-10-29 | 2026-08-15 | — | 2026-08-10 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryNCT06161441Pathological complete response (pCR) as evaluated by blinded independent pathological review (BIPR) in post-treatment resected tumor samples | Phase 2 | Active, not recruiting | Drug: Fianlimab, Cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo | Resectable Non-small Cell Lung Cancer | 195 | 2024-07-16 | 2026-08-24 | in 4 d | 2026-08-10 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort) | Phase 2 | Recruiting | Drug: HER3-DXd | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer | 740 | 2024-02-26 | 2027-09-01 | in 377 d | 2026-08-10 |
| AZN | AstraZeneca | — | Volrustomig Priming Regimens Exploratory Phase II Platform StudyNCT06448754Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 2 | Recruiting | Drug: Volrustomig, Carboplatin, Pemetrexed, Ramucirumab, Paclitaxel | Non-small Cell Lung Cancer | 180 | 2024-08-27 | 2027-07-30 | in 344 d | 2026-08-10 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)NCT07361497Progression-free survival (PFS) by blinded independent central review (BICR) (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1) | Phase 3 | Recruiting | Drug: Pumitamig, Durvalumab | Non-small Cell Lung Cancer (NSCLC) | 850 | 2026-03-16 | 2030-09-18 | in 1,490 d | 2026-08-10 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)NCT07361510Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Phase 3 | Recruiting | Drug: Pumitamig, Pembrolizumab | Non-Small Cell Lung Cancer (NSCLC) | 750 | 2026-03-12 | 2031-10-14 | in 1,881 d | 2026-08-10 |
| PFE | Pfizer | $155.3B | A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLCNCT07556549observationalAge at Start of Lorlatinib Treatment | — | Active, not recruiting | Drug: Lorlatinib | Non-Small Cell Lung Cancer ALK-positive | 50 | 2026-05-18 | 2026-08-30 | in 10 d | 2026-08-10 |
| RIGL | Rigel Pharmaceuticals | $815M | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid TumorsNCT07704658Area Under the Plasma Concentration-Time Curve from zero to infinity (AUC0-inf) | Phase 4 | Recruiting | Drug: Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive | NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer, Solid Tumor Malignancies, Advanced Malignancies | 12 | 2026-03-04 | 2027-07-30 | in 344 d | 2026-08-10 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsNCT06561685Phase Ia: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) | Phase 1 | Recruiting | Drug: LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel | Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor | 340 | 2024-09-19 | Oct 2027 | ≤ 437 d | 2026-08-07 |
| LLY | Eli Lilly and Company | $1.15T | Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerNCT06890598Part A: Disease-Free Survival (DFS) by Investigator Assessment | Phase 3 | Recruiting | Drug: Olomorasib, Pembrolizumab, Durvalumab, Placebo | Carcinoma, Non-Small-Cell Lung | 700 | 2025-03-27 | May 2029 | ≤ 1,015 d | 2026-08-07 |
| AMGN | Amgen | $229.9B | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)NCT07531095Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | Drug: ZL-1310, Tarlatamab, Durvalumab | Small Cell Lung Cancer | 160 | 2026-04-21 | 2028-05-21 | in 640 d | 2026-08-07 |
| 4568.T | Daiichi Sankyo | $31.7B | Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung CancerNCT07535359expanded access | — | Available | Drug: Ifinatamab Deruxtecan | SCLC, Extensive-stage Small Cell Lung Cancer | — | — | — | — | 2026-08-07 |
| 051910.KS | LG Chem | $13.7B | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C MutationNCT07752875Phase 1: Number of participants with dose-limiting toxicities (DLTs) | Phase 1/2 | Not yet recruiting | Drug: LG00313112 | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Pancreatic Cancer, Locally Advanced Unresectable or Metastatic Solid Tumor | 250 | 2026-12-01 | 2032-10-31 | in 2,264 d | 2026-08-07 |
| AZN | AstraZeneca | — | Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)NCT02542293results2022-05-24Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set | Phase 3 | Active, not recruiting | Biological: Durvalumab +Tremelimumab · Drug: Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin | Non Small Cell Lung Carcinoma NSCLC | 953 | 2015-11-03 | 2020-09-21actual | — | 2026-08-06 |
| AZN | AstraZeneca | — | A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer PatientsNCT03706690results2025-02-12Progression-Free Survival (PFS) (Modified Intent-to-Treat [mITT] Set) | Phase 3 | Active, not recruiting | Drug: Durvalumab · Other: Placebo | Carcinoma, Non-Small-Cell Lung | 407 | 2018-11-27 | 2024-06-23actual | — | 2026-08-06 |
| AZN | AstraZeneca | — | Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentNCT05261399Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib. | Phase 3 | Active, not recruiting | Drug: Savolitinib, Osimertinib, Pemetrexed, Cisplatin, Carboplatin | Carcinoma, Non-Small-Cell Lung | 341 | 2022-08-03 | 2026-07-06actual | — | 2026-08-06 |
| AZN | AstraZeneca | — | Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRmNCT055468663-year disease-free survival (DFS) rate by investigator assessment | Phase 2 | Active, not recruiting | Drug: Osimertinib | Non-small Cell Lung Cancer | 51 | 2023-02-09 | 2029-06-30 | in 1,045 d | 2026-08-06 |
| AZN | AstraZeneca | — | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationNCT05877599Module 1, Part 1: Safety of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours | Phase 1 | Recruiting | Biological: NT-175 | Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer, Myeloid Neoplasms (AML/MDS) | 45 | 2023-07-12 | 2029-07-31 | in 1,076 d | 2026-08-06 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerNCT06203210Overall Survival (OS) | Phase 3 | Recruiting | Drug: Ifinatamab deruxtecan, Topotecan, Amrubicin, Lurbinectedin | Small Cell Lung Cancer | 540 | 2024-05-21 | 2028-01-30 | in 528 d | 2026-08-06 |
| NUVL | Nuvalent Inc. | $9.0B | Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid TumorsNCT06834074expanded access | — | Available | Drug: NVL-655 | Non Small Cell Lung Cancer, ALK-positive Non-small Cell Lung Cancer (NSCLC) | — | — | — | — | 2026-08-06 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NCT06881784Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C) | Phase 3 | Recruiting | Drug: daraxonrasib, docetaxel | NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC (Advanced Non-small Cell Lung Cancer) | 590 | 2025-05-06 | 2027-12-01 | in 468 d | 2026-08-06 |
| STRO | Sutro Biopharma, Inc. | $365M | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerNCT07227168Part 1A: Number of participants with Dose-limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: STRO-004, Pembrolizumab | Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer | 200 | 2025-11-07 | Dec 2027 | ≤ 498 d | 2026-08-06 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | A Study of IOV-5001 in Adults With Advanced Solid TumorsNCT07743723Phase 1: Safety Assessment | Phase 1/2 | Not yet recruiting | Biological: IOV-5001 | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumors, Unresectable Solid Tumor | 106 | Aug 2026 | Mar 2034 | ≤ 2,780 d | 2026-08-06 |
| EXEL | Exelixis | $13.2B | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | Drug: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab, Nivolumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail | Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI) | 1,394 | 2021-12-14 | 2027-01-31 | in 164 d | 2026-08-05 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031 | Phase 1 | Recruiting | Drug: LY4052031 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 420 | 2024-07-01 | May 2027 | ≤ 284 d | 2026-08-05 |
| BNTX | BioNTech SE | — | A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)NCT07111520Part 1 - Occurrence of dose limiting toxicities (DLTs) within a participant | Phase 1/2 | Recruiting | Drug: BNT326, Pumitamig | Non-small Cell Lung Cancer | 880 | 2025-09-22 | Nov 2028 | ≤ 833 d | 2026-08-05 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsNCT07277413Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3) | Phase 1 | Recruiting | Drug: IDE892, IDE397 | NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma | 260 | 2026-03-04 | 2028-04-30 | in 619 d | 2026-08-05 |
| BMY | Bristol-Myers Squibb | $134.9B | Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer TreatmentsNCT06448793observationalResponses to qualitative interview questions | — | Completed | Drug: Approved Non-small Cell Lung Cancer (NSCLC) therapies | Non-small Cell Lung Cancer (NSCLC) | 650 | 2024-11-25 | 2025-10-31actual | — | 2026-08-04 |
| ISRG | Intuitive Surgical | $138.2B | European Real-World Registry for Use of the Ion Endoluminal SystemNCT06923774observationalDiagnostic Yield | — | Recruiting | Device: Ion endoluminal system | Pulmonary Nodule, Lung Cancer | 1,200 | 2025-09-09 | Oct 2029 | ≤ 1,168 d | 2026-08-04 |
| NTRA | Natera, Inc. | $44.9B | A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.NCT07689812To demonstrate that ctDNA-guided intermittent ICI therapy results in at least 50% of patients who do not reinitiate systemic therapy prior to 6 months from randomization. | Not applicable | Not yet recruiting | Device: Signatera Genome ultra-sensitive ctDNA blood test | NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC, Melanoma (Skin Cancer), Melanoma (Skin) Stage IV, CRC, MSI High Colorectal Cancer, DMMR Colorectal Cancer, RCC, Renal Cell Cancer, RCC, Solid Tumors, Metastatic Solid Tumors, Advanced Solid Tumors, Advanced Solid Tumors Cancer | 920 | Dec 2026 | Dec 2033 | ≤ 2,690 d | 2026-08-04 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsNCT06128551Number of patients with adverse events (AEs) in Phase 1b | Phase 1/2 | Recruiting | Drug: Elironrasib, Daraxonrasib | Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma | 534 | 2023-11-14 | Dec 2028 | ≤ 864 d | 2026-08-03 |
| AZN | AstraZeneca | — | Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.NCT06376097observationalAbsolute number and frequency of false-negative lung nodules . | — | Recruiting | — | Lung Cancer | 1,000 | 2023-04-19 | 2026-11-29 | in 101 d | 2026-08-03 |
| AZN | AstraZeneca | — | A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerNCT06868277Overall Survival (OS) | Phase 3 | Recruiting | Biological: Rilvegostomig, Pembrolizumab | Carcinoma, Non-Small Cell Lung | 830 | 2025-04-10 | 2030-01-17 | in 1,246 d | 2026-08-03 |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsNCT07185997Progression Free Survival (PFS) determined by blinded independent central review (BICR) | Phase 3 | Recruiting | Drug: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice | Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing, EGFR PACC, EGFR Uncommon Mutations | 480 | 2025-12-17 | Feb 2029 | ≤ 923 d | 2026-08-03 |
| AZN | AstraZeneca | — | Lung Cancer Screening Implementation Project in the Brazilian Public Health Care System (LUSIP)NCT07279948observational• Proportion of negative cases on screening according to the Lung-RADS classification. | — | Not yet recruiting | — | Lung Cancer | 477 | 2026-08-31 | 2027-01-31 | in 164 d | 2026-08-03 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsNCT07397338Number of patients with adverse events (AEs) | Phase 1/2 | Recruiting | Drug: Daraxonrasib, Elironrasib, Zoldonrasib, Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only), cetuximab (Cohort C2 Only), Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only), Daraxonrasib (Cohort B1 only) | Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC, Colorectal Cancer (CRC), CRC | 370 | 2026-01-30 | May 2029 | ≤ 1,015 d | 2026-08-03 |
| 4568.T | Daiichi Sankyo | $31.7B | Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)NCT04656652results2025-07-23Progression-free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1 Following DS-1062a Versus Docetaxel | Phase 3 | Active, not recruiting | Drug: DS-1062a, Docetaxel | Non-small Cell Lung Cancer | 605 | 2020-12-21 | 2024-05-10actual | — | 2026-07-31 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.NCT05355701Number of participants with dose limiting toxicities (DLTs) (Part 1 and Part 2) | Phase 1 | Recruiting | Drug: PF-07799933, binimetinib, midazolam, fluorouracil, leucovorin, oxaliplatin · Biological: cetuximab | Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1) | 267 | 2022-07-05 | 2028-04-23 | in 612 d | 2026-07-31 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of DS-3939a in Participants With Solid TumorsNCT07739966Part 1: Number of Participants With Dose-limiting Toxicities (DLTs) | Phase 1/2 | Not yet recruiting | Drug: DS-3939a, Pembrolizumab, Carboplatin, Pemetrexed, DS-1103a | Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer | 400 | 2026-10-01 | 2030-07-31 | in 1,441 d | 2026-07-31 |
| AZN | AstraZeneca | — | A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLCNCT04606771results2024-09-24Objective Response Rate (ORR) | Phase 2 | Active, not recruiting | Drug: Osimertinib + Savolitinib, Savolitinib + Placebo | Non-Small Cell Lung Cancer | 30 | 2020-09-28 | 2022-12-21actual | — | 2026-07-30 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersNCT05891171Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Drug: AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin | Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC) | 40 | 2023-10-13 | Sep 2027 | ≤ 406 d | 2026-07-30 |
| PFE | Pfizer | $155.3B | A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaNCT03460977Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD) | Phase 1 | Recruiting | Drug: Mervometostat (PF-06821497), Enzalutamide, Itraconazole | Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL) | 453 | 2018-04-17 | 2028-04-20 | in 609 d | 2026-07-29 |
| INBX | Inhibrx Biosciences, Inc | $1.4B | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)NCT04198766Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab | Phase 1/2 | Recruiting | Drug: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2) | Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer | 340 | 2019-12-10 | Jul 2033 | ≤ 2,537 d | 2026-07-29 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNCT04736173Progression-free Survival (PFS) | Phase 2 | Active, not recruiting | Drug: Domvanalimab, Zimberelimab, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab | Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer | 169 | 2021-02-08 | May 2027 | ≤ 284 d | 2026-07-29 |
| BMY | Bristol-Myers Squibb | $134.9B | Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)NCT07100080Recommended Phase 3 Dose (RP3D) of BMS-986507 | Phase 2/3 | Recruiting | Drug: Iza-bren, Carboplatin, Cisplatin, Pemetrexed | Non-Small Cell Lung Cancer | 500 | 2025-11-05 | 2028-12-15 | in 848 d | 2026-07-29 |
| ABBV | AbbVie | $457.5B | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT04928846Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR) | Phase 3 | Recruiting | Biological: Telisotuzumab Vedotin · Drug: Docetaxel | Non Small Cell Lung Cancer | 768 | 2022-03-25 | Dec 2028 | ≤ 864 d | 2026-07-28 |
| AZN | AstraZeneca | — | A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.NCT05984277Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1) | Phase 3 | Active, not recruiting | Drug: Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed | Metastatic Non-small Cell Lung Cancer | 895 | 2023-10-24 | 2029-02-28 | in 923 d | 2026-07-28 |
| CMPX | Compass Therapeutics | $430M | A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesNCT06150664Cohort 1: Evaluate the safety and tolerability of escalating doses of CTX-8371 | Phase 1 | Recruiting | Drug: CTX-8371 | Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma | 85 | 2024-03-19 | Dec 2026 | ≤ 133 d | 2026-07-28 |
| AZN | AstraZeneca | — | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsNCT06218914Part A (Dose Escalation): Evaluate the safety of KRAS TCRTs in subjects with unresectable, advanced, and/or metastatic solid tumors | Phase 1 | Recruiting | Biological: NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D | Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D | 108 | 2024-03-22 | 2027-08-30 | in 375 d | 2026-07-28 |
| SMMT | Summit Therapeutics | $10.2B | Phase III Study of AK112 for NSCLC PatientsNCT06396065Progression-free survival (PFS) | Phase 3 | Active, not recruiting | Drug: AK112 Injection, Placebo Injection | Non-Squamous Non-small Cell Lung Cancer | 420 | 2023-05-04 | 2025-04-12actual | — | 2026-07-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Lung Cancer is matched — 84 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Non-Small Cell Lung Cancer
- Lung Cancer
- Non Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Small Cell Lung Cancer
- NSCLC
- Lung Neoplasms
- Non-small Cell Lung Cancer (NSCLC)
- Non-Small-Cell Lung Carcinoma
- Non-Small-Cell Lung Cancer
- Small Cell Lung Carcinoma
- Carcinoma, Non-Small Cell Lung
- NSCLC (Non-small Cell Lung Cancer)
- Advanced Non-Small Cell Lung Cancer
- Small-cell Lung Cancer
- Carcinoma, Non Small Cell Lung
- Non Small Cell Lung Cancer (NSCLC)
- Non-small Cell Lung Carcinoma
- Metastatic Non-small Cell Lung Cancer
- NSCLC (Non-small Cell Lung Carcinoma)
- Extensive-stage Small-cell Lung Cancer
- Non-Small-Cell Lung
- Non-small Cell Lung Cancer Metastatic
- SCLC
- Small Cell Lung Cancer (SCLC)
- Extensive Stage Small Cell Lung Cancer
- Metastatic Non Small Cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Carcinoma
- Advanced Non Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung (NSCLC)
- Extensive-stage Small Cell Lung Cancer
- Lung Cancer (NSCLC)
- NSCLC Stage IV
- Non Small Cell Lung Cancer Metastatic
- Non-squamous Non-small Cell Lung Cancer
- Small Cell Lung Cancer ( SCLC )
- Squamous Non Small Cell Lung Cancer
- Advanced (Inoperable) Non Small Cell Lung Cancer
- Advanced Lung Carcinoma
- Advanced Non-squamous Non-small-cell Lung Cancer
- Advanced or Metastatic NSCLC
- Lung Cancer Metastatic
- Metastatic Lung Cancer
- Non-Small Cell Lung Cancer NSCLC
- Non-small Cell Lung Cancers
- Small Cell Lung Carcinoma Extensive Disease
- Squamous Non-Small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer
- ALK-positive Advanced NSCLC
- ALK-positive NSCLC
- ALK-positive Non-small-cell Lung Cancer
- Advanced NSCLC
- Advanced Non-squamous NSCLC
- Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced/Metastatic Non-Small Cell Lung Cancer
- Carcinoma, Small Cell Lung
- EGFR Mutated Non-small Cell Lung Cancer Patients
- Extensive Disease Small Cell Lung Cancer
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- HER2-mutant Non-Small Cell Lung Cancer
- Locally Advanced or Metastatic NSCLC
- Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Lung Cancer, Non-small Cell
- Metastatic NSCLC
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Metastatic Squamous Non-Small Cell Lung Cancer
- NSCLC Adenocarcinoma
- NSCLC, Recurrent
- Non Small Cell Lung Carcinoma NSCLC
- Non-Small Cell Lung Cancer ALK-positive
- Non-small Cell Lung Cancer Stage III
- Non-small Cell Lung Cancer Stage IV
- Nonsmall Cell Lung Cancer
- Nonsquamous Non Small Cell Lung Cancer
- Nonsquamous Non-small Cell Lung Cancer
- ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
- Recurrent NSCLC
- Relapsed/Refractory Small Cell Lung Cancer
- Resectable Non-Small-Cell Lung Cancer
- Resectable Non-small Cell Lung Cancer
- Squamous Cell Non-small Cell Lung Cancer
- Stage III Non-small Cell Lung Cancer
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Lung Cancer” (a text search, wider than this page)